EP1805307A1 - Protection of biologically active molecules using amphiphiles - Google Patents

Protection of biologically active molecules using amphiphiles

Info

Publication number
EP1805307A1
EP1805307A1 EP05795379A EP05795379A EP1805307A1 EP 1805307 A1 EP1805307 A1 EP 1805307A1 EP 05795379 A EP05795379 A EP 05795379A EP 05795379 A EP05795379 A EP 05795379A EP 1805307 A1 EP1805307 A1 EP 1805307A1
Authority
EP
European Patent Office
Prior art keywords
biologically active
active compound
saint
molecule
sirna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP05795379A
Other languages
German (de)
French (fr)
Other versions
EP1805307B1 (en
Inventor
Marcel Herman Josef Ruiters
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synvolux IP BV
Original Assignee
Synvolux IP BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from NL1027311A external-priority patent/NL1027311C2/en
Priority claimed from NL1027417A external-priority patent/NL1027417C2/en
Application filed by Synvolux IP BV filed Critical Synvolux IP BV
Priority to SI200530618T priority Critical patent/SI1805307T1/en
Priority to PL05795379T priority patent/PL1805307T3/en
Publication of EP1805307A1 publication Critical patent/EP1805307A1/en
Application granted granted Critical
Publication of EP1805307B1 publication Critical patent/EP1805307B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity
    • C12N2320/51—Methods for regulating/modulating their activity modulating the chemical stability, e.g. nuclease-resistance

Definitions

  • the present invention relates to a process to protect a biologically active compound against the effects of for instance enzymes, chemicals, oxygen, radicals or sunlight. Further the invention relates to a vehicle to protect a biological active compound against the effects of for instance enzymes, chemicals, oxygen, radicals or sunlight. The invention also relates to the application of a SAINT-molecule to protect a biological active compound against the effects of for instance enzymes, chemicals, oxygen, radicals or sunlight.
  • biologically active compounds such as siRNA, RNA, DNA, proteins and peptides are sensitive for the effects (e.g. degradation) of for instance enzymes, chemicals, oxygen, radicals or sunlight.
  • biologically active compounds such as siRNA, RNA, DNA, oligonucleotides or derivates thereof
  • proteins and peptides can only be transported as dry matter, or as a stabilized, glycerol or DMSO containing solution.
  • the solutions to be transported or dry matters are kept on dry ice, or are cooled in another way. Consequently, the transportation of these compounds is very expensive.
  • Another disadvantage of transporting biologically active compounds as dry matter is the fact that during the dissolution of the biologically active compound a conformational change may occur. As a result, not all biologically active matter will regain its original function.
  • glycerol (or DMSO) has shown to have a negative effect on the activity of the biologically active compound when the biologically active compound is diluted before application.
  • the solution found in the state of the art to circumvent these disadvantages is to replace the glycerol (or DMSO) by threhalose.
  • Threhalose is a sugar. Although in theory no conformational change occurs when dissolving the biologically active compound in threhalose, there are some other disadvantages when using threhalose. A particular disadvantage is that threhalose has an adverse effect on the desired enzymatic activity of the proteins.
  • threhalose is not used to package DNA, RNA, siRNA en oligonucleotides or derivatives thereof. After complexation with threhalose (and other sugars) DNA,RNA etc, are laboriously to be dissolved, as they can also be characterized as sugars.
  • the present invention aims at solving the disadvantages mentioned above.
  • the invention aims to provide for a process to protect a biologically active compound against the effects of for instance enzymes, chemicals, oxygen, radicals or sunlight.
  • the invention also aims to provide for a vehicle to protect a biologically active compound against the effects of enzymes, chemicals, oxygen, radicals or sunlight whereby the disadvantages mentioned above can be circumvented.
  • transport is understood to mean both the packaging of the biologically active compound in a transportation container, and the subsequent conveyance of this container by means of transportation means, such as carriers, etc., as well as the transport of individual biologically active molecules, which are each separately enwrapped by the protecting compounds.
  • the present invention provides for a process as mentioned in the preamble, which process is characterised by the measures according to claim 1.
  • the biologically active compound has become completely protected from effects of enzymes, chemicals, oxygen, radicals or sunlight. Furthermore, completely no or no functional inhibitory conformational changes of the biological compound occur.
  • the invention provides for a vehicle as mentioned in the pre-amble, characterized by the measures as described in claim 4.
  • the vehicle of the present invention provides a very reliable and simple solution for transporting a biologically active compound in such a way that the biologically active compound will not become damaged, for instance by the effect of enzymes, chemicals, oxygen, radicals or sunlight, or a conformational change occurs.
  • a SAINT-molecule protects a biologically active compound against the effect of for instance enzymes, chemicals, oxygen, radicals or sunlight, which is characterized in that the biologically active compound is contacted with the biologically active compound, causing the biologically active compounds to interact with the SAINT-molecule.
  • the biologically active compound which can be chosen from, for instance, siRNA, RNA, DNA, oligonucleotides or derivatives thereof, proteins and peptides, is actually enwrapped by one ore more SAINT-molecules.
  • the saint molecules may all be of the same kind, but it is also possible that a mixture of different SAINT-molecules is applied, which can be connected to the biological active compound. This interaction is a hydrogen-bond.
  • the vehicle of the present invention consisting of the biologically active compound and the SAINT-molecule or SAINT-molecules enwrapping it, can be kept without occurring a separation of the biologically active compound and the SAINT-molecules.
  • the biologically active compound when the biologically active compound has to fulfil its function, it is not suffering any functional hindrance from the SAINT-molecules present. Therefore the biologically active compounds can freely operate and can easily be applied in basically any biological assay.
  • a remarkably great advantage of the present invention is that no separation of the SAINT-molecule (s) from the biological active compound is needed, because the saint-molecule (s) have no inhibitory effect in the buffer. The molecule will be diluted to such a great extent, that no inhibitory effect will be shown. Furthermore it is biologically degradable, without forming any toxic compounds.
  • siRNA when directed to a specific gene, is able to silence the gene-expression by inhibition of the mRNA translation.
  • SiRNA needs to be stored as dried powder and, after dissolution, aliquots are stored at -2O 0 C. Regardless of aliquots being prepared, the reproducibility of (the results obtained over time using) such aliquots is weak.
  • the delivery of siRNA to cells has been described in patents EP-0755924 and US 5,853,694.
  • siRNA 25 micrograms of siRNA were complexed with 0,5 ml of SAINT-MIX. Per transfection 20 ⁇ l of this (preservation) -complex is used. Transfection was performed as described in detail in EP-0755924.
  • the efficacy of the siRNA-transfection is validated by measuring the enzyme activity of the silenced gene according to a standard enzyme assay. Lifetime of the enzyme is approximately 5 days. Therefore, after one single transfection with 1 Dg siRNA, about 50% enzyme activity can be measured after 48 hours and almost no enzyme activity can be measured after 10 days, as shown in the figure 1 below.
  • siRNA complexed with SAINT-RED is active over a 9 month- period while the aliguoted siRNA has lost almost all its activity within 2 days.
  • results show that the siRNA/SAINT prevention complex is even more active, up to 5 months, when compared with the freshly prepared siRNA/SAINT complex. This indicates the strong protective character of SAINT-molecules towards biologically active compounds.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)

Abstract

Vehicle for the transport of a chosen molecule to a cell, comprising a SAINT-molecule which is bound to the chosen molecule by means of an electrostatic interaction, in which the SAINT-molecule is coupled to the linker molecule and the linker molecule is coupled to the cell specific ligand and in which the SAINT-molecule is covalently bound to the linker molecule.

Description

Protection of biologically active molecules using amphiphiles
The present invention relates to a process to protect a biologically active compound against the effects of for instance enzymes, chemicals, oxygen, radicals or sunlight. Further the invention relates to a vehicle to protect a biological active compound against the effects of for instance enzymes, chemicals, oxygen, radicals or sunlight. The invention also relates to the application of a SAINT-molecule to protect a biological active compound against the effects of for instance enzymes, chemicals, oxygen, radicals or sunlight.
In general, biologically active compounds, such as siRNA, RNA, DNA, proteins and peptides are sensitive for the effects (e.g. degradation) of for instance enzymes, chemicals, oxygen, radicals or sunlight. For example, in many cases biologically active compounds, such as siRNA, RNA, DNA, oligonucleotides or derivates thereof, proteins and peptides can only be transported as dry matter, or as a stabilized, glycerol or DMSO containing solution. The solutions to be transported or dry matters are kept on dry ice, or are cooled in another way. Consequently, the transportation of these compounds is very expensive.
Another disadvantage of transporting biologically active compounds as dry matter is the fact that during the dissolution of the biologically active compound a conformational change may occur. As a result, not all biologically active matter will regain its original function.
Also the transport of the biologically active compound in a (buffered) glycerol (or DMSO) containing solution has disadvantages. Glycerol (or DMSO) has shown to have a negative effect on the activity of the biologically active compound when the biologically active compound is diluted before application. The solution found in the state of the art to circumvent these disadvantages is to replace the glycerol (or DMSO) by threhalose. Threhalose is a sugar. Although in theory no conformational change occurs when dissolving the biologically active compound in threhalose, there are some other disadvantages when using threhalose. A particular disadvantage is that threhalose has an adverse effect on the desired enzymatic activity of the proteins. In the state of the art threhalose is not used to package DNA, RNA, siRNA en oligonucleotides or derivatives thereof. After complexation with threhalose (and other sugars) DNA,RNA etc, are laboriously to be dissolved, as they can also be characterized as sugars.
The present invention aims at solving the disadvantages mentioned above.
In particular, the invention aims to provide for a process to protect a biologically active compound against the effects of for instance enzymes, chemicals, oxygen, radicals or sunlight. The invention also aims to provide for a vehicle to protect a biologically active compound against the effects of enzymes, chemicals, oxygen, radicals or sunlight whereby the disadvantages mentioned above can be circumvented. The word "transport" is understood to mean both the packaging of the biologically active compound in a transportation container, and the subsequent conveyance of this container by means of transportation means, such as carriers, etc., as well as the transport of individual biologically active molecules, which are each separately enwrapped by the protecting compounds.
To meet at least one of the aforementioned aims, the present invention provides for a process as mentioned in the preamble, which process is characterised by the measures according to claim 1. Herewith the advantage is reached that the biologically active compound has become completely protected from effects of enzymes, chemicals, oxygen, radicals or sunlight. Furthermore, completely no or no functional inhibitory conformational changes of the biological compound occur.
Furthermore the invention provides for a vehicle as mentioned in the pre-amble, characterized by the measures as described in claim 4. The vehicle of the present invention provides a very reliable and simple solution for transporting a biologically active compound in such a way that the biologically active compound will not become damaged, for instance by the effect of enzymes, chemicals, oxygen, radicals or sunlight, or a conformational change occurs.
According to a further aspect of the invention an application is provided in which a SAINT-molecule protects a biologically active compound against the effect of for instance enzymes, chemicals, oxygen, radicals or sunlight, which is characterized in that the biologically active compound is contacted with the biologically active compound, causing the biologically active compounds to interact with the SAINT-molecule. ■ By means of the invention, the biologically active compound, which can be chosen from, for instance, siRNA, RNA, DNA, oligonucleotides or derivatives thereof, proteins and peptides, is actually enwrapped by one ore more SAINT-molecules. The saint molecules may all be of the same kind, but it is also possible that a mixture of different SAINT-molecules is applied, which can be connected to the biological active compound. This interaction is a hydrogen-bond.
It has been shown that the vehicle of the present invention, consisting of the biologically active compound and the SAINT-molecule or SAINT-molecules enwrapping it, can be kept without occurring a separation of the biologically active compound and the SAINT-molecules. Nevertheless, it has also been shown that, when the biologically active compound has to fulfil its function, it is not suffering any functional hindrance from the SAINT-molecules present. Therefore the biologically active compounds can freely operate and can easily be applied in basically any biological assay. A remarkably great advantage of the present invention is that no separation of the SAINT-molecule (s) from the biological active compound is needed, because the saint-molecule (s) have no inhibitory effect in the buffer. The molecule will be diluted to such a great extent, that no inhibitory effect will be shown. Furthermore it is biologically degradable, without forming any toxic compounds.
The invention has been described in essence in the above. Based on the description above and the attached claims, a person skilled in the art will easily be able to develop further embodiments, which all will fall within the scope of the present invention.
EXAMPLE
One of the most sensitive and at this moment frequently used biologically active compounds is siRNA. SiRNA, when directed to a specific gene, is able to silence the gene-expression by inhibition of the mRNA translation.
SiRNA needs to be stored as dried powder and, after dissolution, aliquots are stored at -2O0C. Regardless of aliquots being prepared, the reproducibility of (the results obtained over time using) such aliquots is weak. The delivery of siRNA to cells has been described in patents EP-0755924 and US 5,853,694.
To illustrated the present invention we here show data concerning the preservation of siRNA by the use of SAINT-molecules.
Method:
25 micrograms of siRNA were complexed with 0,5 ml of SAINT-MIX. Per transfection 20 μl of this (preservation) -complex is used. Transfection was performed as described in detail in EP-0755924.
The efficacy of the siRNA-transfection is validated by measuring the enzyme activity of the silenced gene according to a standard enzyme assay. Lifetime of the enzyme is approximately 5 days. Therefore, after one single transfection with 1 Dg siRNA, about 50% enzyme activity can be measured after 48 hours and almost no enzyme activity can be measured after 10 days, as shown in the figure 1 below.
Remaining enzyme activity after transfection of 1 ug siRNA with SAINT-RED
□Enzymeactivity
Oday 2days 10days
Figure 1.
Over a 9 month-period, we compared the siRNA stored at -20°C degrees versus the siRNA/SAINT-RED preservation complex. Enzyme activity was measured 48 hours after transfection. Results have been depicted in Figure 2.
0 1 day 2 days 5 months 9 months storage time
Figure 2 .
The figure clearly shows that siRNA complexed with SAINT-RED is active over a 9 month- period while the aliguoted siRNA has lost almost all its activity within 2 days. Moreover the results show that the siRNA/SAINT prevention complex is even more active, up to 5 months, when compared with the freshly prepared siRNA/SAINT complex. This indicates the strong protective character of SAINT-molecules towards biologically active compounds.

Claims

1. A process for the protection of a biologically- active compound against the effect of for instance enzymes, chemicals, oxygen, radicals or sunlight, characterised in that it contains the step of bringing the biologically active compound in contact with a SAINT- molecule.
2. The process according to claim 1, characterised in that this step comprises the contacting of a biologically active compound with a mixture of SAINT- molecules.
3. The process according to claims 1 or 2, characterised in that the biologically active compound is bound to at least one SAINT-molecule by means of electrostatic interaction.
4. A vehicle for the protection of a biologically active compound against the effect of for instance, enzymes, chemicals, oxygen, radicals or sunlight, characterised in that the vehicle comprises of the biologically active compound an at least one SAINT- molecule bound to it.
5. The vehicle according to claim 4, characterised in that the at least one SAINT-molecule is bound to the biologically active compound by means of electrostatic interaction.
6. A process to preserve a biologically active compound, characterised in that it comprises the step of combining the biologically active compound with a SAINT- molecule or a mixture thereof.
7. The application of a SAINT-molecule for the protection of a biologically active compound against the effect of for instance enzymes, chemicals, oxygen, radical or sunlight, whereby the biologically active compound is brought in contact with a SAINT-molecule in such a way that the biologically active compound interacts with the SAINT-molecule through electrostatic interaction.
EP05795379A 2004-10-21 2005-10-20 Protection of biologically active molecules using amphiphiles Active EP1805307B1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
SI200530618T SI1805307T1 (en) 2004-10-21 2005-10-20 Protection of biologically active molecules using amphiphiles
PL05795379T PL1805307T3 (en) 2004-10-21 2005-10-20 Protection of biologically active molecules using amphiphiles

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
NL1027311A NL1027311C2 (en) 2004-10-21 2004-10-21 New vehicle, useful for the transport to the nucleus of a DNA-modifying enzyme/molecule which is combined with a SAINT-molecule or a combination of several entities
NL1027417A NL1027417C2 (en) 2004-10-21 2004-11-04 New vehicle, useful for the transport to the nucleus of a DNA-modifying enzyme/molecule which is combined with a SAINT-molecule or a combination of several entities
NL1027479A NL1027479C2 (en) 2004-10-21 2004-11-10 Protection of biologically active molecules with the help of amphiphiles.
PCT/NL2005/000752 WO2006043809A1 (en) 2004-10-21 2005-10-20 Protection of biologically active molecules using amphiphiles

Publications (2)

Publication Number Publication Date
EP1805307A1 true EP1805307A1 (en) 2007-07-11
EP1805307B1 EP1805307B1 (en) 2009-01-14

Family

ID=35583431

Family Applications (3)

Application Number Title Priority Date Filing Date
EP05795367A Not-in-force EP1805305B1 (en) 2004-10-21 2005-10-20 Vehicle for the transport of a chosen molecule to a cell
EP05795379A Active EP1805307B1 (en) 2004-10-21 2005-10-20 Protection of biologically active molecules using amphiphiles
EP05795375A Not-in-force EP1805306B1 (en) 2004-10-21 2005-10-20 Vehicle to transport a dna-modifying enzyme to a genome

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP05795367A Not-in-force EP1805305B1 (en) 2004-10-21 2005-10-20 Vehicle for the transport of a chosen molecule to a cell

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP05795375A Not-in-force EP1805306B1 (en) 2004-10-21 2005-10-20 Vehicle to transport a dna-modifying enzyme to a genome

Country Status (16)

Country Link
US (4) US20070225230A1 (en)
EP (3) EP1805305B1 (en)
JP (2) JP2008517904A (en)
KR (1) KR20070073796A (en)
AT (3) ATE420173T1 (en)
AU (1) AU2005296360B2 (en)
CA (2) CA2583860A1 (en)
DE (3) DE602005012420D1 (en)
DK (3) DK1805307T3 (en)
ES (3) ES2318549T3 (en)
NL (1) NL1027479C2 (en)
NO (3) NO20071600L (en)
PL (3) PL1805307T3 (en)
PT (3) PT1805306E (en)
SI (3) SI1805307T1 (en)
WO (3) WO2006043811A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101848703B (en) * 2007-09-07 2014-04-16 辛沃鲁克斯Ip有限公司 Improved liposomes and uses thereof
DE102008032594A1 (en) 2008-07-11 2010-01-14 Qiagen Gmbh transfection

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5077211A (en) * 1988-07-06 1991-12-31 Applied Genetics, Inc. Purification and administration of dna repair enzymes
US5641625A (en) * 1992-05-22 1997-06-24 Isis Pharmaceuticals, Inc. Cleaving double-stranded DNA with peptide nucleic acids
KR100252547B1 (en) * 1991-09-05 2000-09-01 프레드 마리얀스키 Targeted delivery of poly- or oligonucleotides to cells
US6083741A (en) * 1994-11-17 2000-07-04 Imperial College Of Science Technology And Medicine Internalisation of DNA, using conjugates of poly-l-lysine and an integrin receptor ligand
NL1000884C2 (en) * 1995-07-25 1997-01-28 Univ Groningen Transport vehicles for macromolecules.
US6726894B1 (en) * 1995-07-25 2004-04-27 Synvolux Ip B.V. Transport vehicles for macromolecules
US5958894A (en) * 1997-04-04 1999-09-28 Megabios Corporation Amphiphilic biguanide derivatives
EP1401818A2 (en) * 2001-05-30 2004-03-31 Targesome, Inc. Targeted multivalent macromolecules
GB0117964D0 (en) * 2001-07-24 2001-09-19 Imp College Innovations Ltd Control of gene expression
CA2455598A1 (en) * 2001-07-27 2003-02-13 Targesome, Inc. Lipid constructs as therapeutic and imaging agents
GB0124391D0 (en) * 2001-10-11 2001-11-28 Gene Expression Technologies L Control of gene expression
CA2487274A1 (en) * 2002-05-06 2003-11-13 Nucleonics Inc. Spermine chemically linked to lipids and cell-specific targeting molecules as a transfection agent
US20060247192A1 (en) * 2002-12-05 2006-11-02 Jenkinson John D Control of apoptosis
AU2003225410A1 (en) * 2003-03-21 2004-10-11 Academisch Ziekenhuis Leiden Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure
ITMI20030821A1 (en) * 2003-04-18 2004-10-19 Internat Ct For Genetic En Gineering And CHEMICAL POLYPEPTIDES AND THEIR USE.

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2006043809A1 *

Also Published As

Publication number Publication date
SI1805305T1 (en) 2009-06-30
DK1805306T3 (en) 2009-04-20
DE602005012303D1 (en) 2009-02-26
PL1805306T3 (en) 2009-06-30
US20070224589A1 (en) 2007-09-27
EP1805306A1 (en) 2007-07-11
EP1805305B1 (en) 2009-01-07
PT1805305E (en) 2009-04-13
US20070225230A1 (en) 2007-09-27
DK1805305T3 (en) 2009-11-23
CA2584633A1 (en) 2006-04-27
DE602005012304D1 (en) 2009-02-26
SI1805307T1 (en) 2009-06-30
EP1805307B1 (en) 2009-01-14
JP2008517903A (en) 2008-05-29
CA2583860A1 (en) 2006-04-27
EP1805306B1 (en) 2009-01-07
AU2005296360B2 (en) 2010-06-10
US20070224680A1 (en) 2007-09-27
ATE420954T1 (en) 2009-01-15
PT1805306E (en) 2009-04-13
WO2006043810A1 (en) 2006-04-27
NL1027479C2 (en) 2006-05-01
ATE420172T1 (en) 2009-01-15
US20080085273A1 (en) 2008-04-10
DK1805307T3 (en) 2009-05-04
NO20071599L (en) 2007-06-26
EP1805305A1 (en) 2007-07-11
ES2318550T3 (en) 2009-05-01
ATE420173T1 (en) 2009-01-15
NO20071600L (en) 2007-07-11
ES2318548T3 (en) 2009-05-01
PL1805305T3 (en) 2009-06-30
PT1805307E (en) 2009-04-13
WO2006043811A1 (en) 2006-04-27
JP2008517904A (en) 2008-05-29
KR20070073796A (en) 2007-07-10
NO20071601L (en) 2007-06-21
AU2005296360A1 (en) 2006-04-27
SI1805306T1 (en) 2009-06-30
PL1805307T3 (en) 2009-06-30
DE602005012420D1 (en) 2009-03-05
ES2318549T3 (en) 2009-05-01
WO2006043809A1 (en) 2006-04-27
CA2584633C (en) 2016-11-22

Similar Documents

Publication Publication Date Title
Shigenaga et al. Inflammation and NOx-induced nitration: assay for 3-nitrotyrosine by HPLC with electrochemical detection
Cogoi et al. The regulatory G4 motif of the Kirsten ras (KRAS) gene is sensitive to guanine oxidation: implications on transcription
Knight et al. Role of lipid peroxidation as a mechanism of liver injury after acetaminophen overdose in mice
Lucero et al. Internal trehalose protects endocytosis from inhibition by ethanol in Saccharomyces cerevisiae
Bertschinger et al. Disassembly of polyethylenimine-DNA particles in vitro: Implications for polyethylenimine-mediated DNA delivery
Hansen et al. Antioxidative stress proteins and their gene expression in brown trout (Salmo trutta) from three rivers with different heavy metal levels
Mandl‐Weber et al. The novel inhibitor of histone deacetylase resminostat (RAS2410) inhibits proliferation and induces apoptosis in multiple myeloma (MM) cells
Homaei Immobilization of Penaeus merguiensis alkaline phosphatase on gold nanorods for heavy metal detection
Zhang et al. Long-term hepatotoxicity of polyethylene-glycol functionalized multi-walled carbon nanotubes in mice
Gogoi et al. A versatile method for the preparation of conjugates of peptides with DNA/PNA/analog by employing chemo-selective click reaction in water
FR2838442A1 (en) New double-stranded oligonucleotides, useful e.g. for treatment and diagnosis of tumors, comprise complementary strands with single-stranded overhangs
Barbey et al. Inducible dissociation of SCFMet30 ubiquitin ligase mediates a rapid transcriptional response to cadmium
Salomon et al. Modified dsRNAs that are not processed by Dicer maintain potency and are incorporated into the RISC
Fath et al. Association of yeast RNA polymerase I with a nucleolar substructure active in rRNA synthesis and processing
Shen et al. Chinonin, a novel drug against cardiomyocyte apoptosis induced by hypoxia and reoxygenation
Rodnina et al. Mechanism of peptide bond formation on the ribosome
Ghio et al. Iron homeostasis in the lung
EP1805307A1 (en) Protection of biologically active molecules using amphiphiles
Barrera et al. Effects of 4-hydroxynonenal, a product of lipid peroxidation, on cell proliferation and ornithine decarboxylase activity
Chauhan et al. The SUMO‐specific protease SENP1 deSUMOylates p53 and regulates its activity
Hong et al. Probucol up-regulates paraoxonase 1 expression in hepatocytes of hypercholesterolemic rabbits
Parker et al. Formation of DNA adducts by formaldehyde-activated mitoxantrone
Ulbrich-Hofmann et al. Soluble and immobilized enzymes in water-miscible organic solvents: glucoamylase and invertase
Zhang et al. MYC is downregulated by a mitochondrial checkpoint mechanism
Sun et al. Sweet delivery–sugar translocators as ports of entry for antisense oligodeoxynucleotides in plant cells

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20070521

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

17Q First examination report despatched

Effective date: 20070926

DAX Request for extension of the european patent (deleted)
GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: ISLER & PEDRAZZINI AG

REF Corresponds to:

Ref document number: 602005012420

Country of ref document: DE

Date of ref document: 20090305

Kind code of ref document: P

REG Reference to a national code

Ref country code: RO

Ref legal event code: EPE

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20090400854

Country of ref document: GR

Ref country code: PT

Ref legal event code: SC4A

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20090406

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2318550

Country of ref document: ES

Kind code of ref document: T3

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

REG Reference to a national code

Ref country code: PL

Ref legal event code: T3

REG Reference to a national code

Ref country code: HU

Ref legal event code: AG4A

Ref document number: E005694

Country of ref document: HU

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20091015

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20091022

Year of fee payment: 5

Ref country code: CZ

Payment date: 20091013

Year of fee payment: 5

Ref country code: DK

Payment date: 20091023

Year of fee payment: 5

Ref country code: EE

Payment date: 20091026

Year of fee payment: 5

Ref country code: ES

Payment date: 20091026

Year of fee payment: 5

Ref country code: FI

Payment date: 20091026

Year of fee payment: 5

Ref country code: HU

Payment date: 20091020

Year of fee payment: 5

Ref country code: IE

Payment date: 20091021

Year of fee payment: 5

Ref country code: IS

Payment date: 20091022

Year of fee payment: 5

Ref country code: LT

Payment date: 20091013

Year of fee payment: 5

Ref country code: LU

Payment date: 20091026

Year of fee payment: 5

Ref country code: MC

Payment date: 20091021

Year of fee payment: 5

Ref country code: SE

Payment date: 20091023

Year of fee payment: 5

Ref country code: TR

Payment date: 20091012

Year of fee payment: 5

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SI

Payment date: 20091009

Year of fee payment: 5

Ref country code: RO

Payment date: 20091013

Year of fee payment: 5

Ref country code: PL

Payment date: 20091008

Year of fee payment: 5

Ref country code: SK

Payment date: 20091016

Year of fee payment: 5

Ref country code: NL

Payment date: 20091030

Year of fee payment: 5

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CY

Payment date: 20091019

Year of fee payment: 5

Ref country code: PT

Payment date: 20091008

Year of fee payment: 5

Ref country code: LV

Payment date: 20091028

Year of fee payment: 5

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20091024

Year of fee payment: 5

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20091029

Year of fee payment: 5

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GR

Payment date: 20091022

Year of fee payment: 5

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BG

Payment date: 20101026

Year of fee payment: 6

REG Reference to a national code

Ref country code: PT

Ref legal event code: MM4A

Free format text: LAPSE DUE TO NON-PAYMENT OF FEES

Effective date: 20110420

BERE Be: lapsed

Owner name: SYNVOLUX IP B.V.

Effective date: 20101031

REG Reference to a national code

Ref country code: NL

Ref legal event code: V1

Effective date: 20110501

LTLA Lt: lapse of european patent or patent extension

Effective date: 20101020

REG Reference to a national code

Ref country code: DK

Ref legal event code: EBP

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20101031

REG Reference to a national code

Ref country code: EE

Ref legal event code: MM4A

Ref document number: E003169

Country of ref document: EE

Effective date: 20101031

REG Reference to a national code

Ref country code: SK

Ref legal event code: MM4A

Ref document number: E 5405

Country of ref document: SK

Effective date: 20101020

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20101031

Ref country code: CZ

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20101020

Ref country code: LV

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20101020

Ref country code: LT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20101020

Ref country code: GR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110503

Ref country code: PT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110420

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110501

Ref country code: HU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20101021

REG Reference to a national code

Ref country code: SI

Ref legal event code: KO00

Effective date: 20110609

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20101020

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110501

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20101020

Ref country code: CY

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20101020

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20101031

Ref country code: SK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20101020

Ref country code: SI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20101021

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20101021

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20101031

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20101020

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20111118

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RO

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20101020

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20101020

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20101021

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20101020

REG Reference to a national code

Ref country code: PL

Ref legal event code: LAPE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20101020

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20101020

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120630

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 11

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 12

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 13

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20221028

Year of fee payment: 18

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20221019

Year of fee payment: 18

Ref country code: DE

Payment date: 20221019

Year of fee payment: 18

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20221026

Year of fee payment: 18

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602005012420

Country of ref document: DE

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL